ストックスクリーナーアプリを入手
0.711
2.60%
-0.019
前日終値:
$0.73
開ける：
$0.74
24時間の取引高:
108.60K
Relative Volume:
0.62
時価総額：
$7.63M
収益：
-
当期純損益:
$-3.28M
株価収益率:
-0.6833
EPS:
-1.0406
ネットキャッシュフロー:
$-4.80M
1週間 パフォーマンス:
-7.66%
1か月 パフォーマンス:
+1.57%
6か月 パフォーマンス:
-14.34%
1年 パフォーマンス:
-35.36%
1日の値動き範囲:
$0.711
$0.7449
1週間の範囲:
$0.711
$0.788
52週間の値動き範囲:
$0.63
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
名前
Pharmacyte Biotech Inc
セクター
電話
(917) 595.2850
住所
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.49 | 2.97B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.01 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.20 | 349.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
4.72 | 358.07M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.37 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc (PMCB) 最新ニュース
PharmaCyte Biotech | SCHEDULE 13G: Others - Moomoo
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Slight Loss, Shares RiseEarnings Call Highlights - dars.gov.et
Price to book forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to sales forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to earnings forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to EBITDA forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to revenue forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech (PMCB) Holds Steady at $0.7: Consolidation Near Key SupportVolume Profile - newsline.com
PMCB Q1 2026 Earnings: Modest Loss Reported Amid Early-Stage DevelopmentEarnings Surprise Report - dars.gov.et
PMCB Technical Analysis & Stock Price Forecast - Intellectia AI
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre‑Revenue Biotech Reports Loss, Shares Slide 3.5%Earnings Surprise Stocks - newsline.com
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023. - marketscreener.com
PharmaCyte Biotech (PMCB) Rises 3.19%: Approaching Resistance Zone Amid Biotech Sector FocusChaikin Flow - newsline.com
PharmaCyte Biotech (PMCB) Slips 3.3% as Stock Nears Critical Support at $0.79Fundamental Weighted - dars.gov.et
PharmaCyte Biotech (PMCB) Jumps 12.76% as Biotech Speculation Heats UpBuyback Factor - The Legal Advocate
PMCBPharmaCyte Biotech Inc Stock Price and Quote - Finviz
PharmaCyte Biotech (PMCB) Edges Higher: Support-Holding Action at $0.81IPO Entry Watch - Newser
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Negative EPS; Stock Rises on Potential Pipeline Progress - Newser
PharmaCyte Biotech Inc. (PMCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PharmaCyte Biotech (PMCB) Rallies 5.6% as Biotech Sentiment ImprovesNHNL Divergence - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Strategic Pipeline ProgressHigh Estimate Range - Newser
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider Loss Amid Strategic Pipeline ProgressShared Momentum Picks - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Revenue $N/A, Matching ViewsGuidance Revision Trend - Newser
TradingKey - TradingKey
PharmaCyte Biotech (PMCB) Stock: Buy or Sell |Risk Report - newser.com
PMCB SEC FilingsPharmacyte Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
PharmaCyte Biotech (PMCB) Stock Take Profit (Gains) 2026-04-20Risk Reward Setups - newsline.com
Aug Intraday: Is PharmaCyte Biotech Inc a good ESG investment2026 Short Interest & Accurate Trade Setup Notifications - baoquankhu1.vn
PharmaCyte Biotech Operating Margin | PMCB - MLQ.ai
EV Market: Should I invest in PharmaCyte Biotech Inc before earningsJobs Report & Weekly High Return Opportunities - baoquankhu1.vn
How liquid is PharmaCyte Biotech Inc stockPortfolio Performance Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is PharmaCyte Biotech (PMCB) Stock Near Support | Price at $0.69, Up 5.96%New Highs New Lows - newsline.com
Aug Ideas: What is the Moat Score of PharmaCyte Biotech Inc2026 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is PharmaCyte Biotech Inc vulnerable to short sellersMarket Sentiment Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
PharmaCyte Biotech Shareholders Approve Governance and Equity Actions - The Globe and Mail
Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB) - Stock Titan
Director at PharmaCyte Biotech (PMCB) gets 119,170 options - Stock Titan
PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67 - Stock Titan
Pharmacyte Biotech Inc (PMCB) 財務データ
収益
当期純利益
現金流量
EPS
Pharmacyte Biotech Inc (PMCB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Silverman Joshua | CEO and President |
Jan 06 '26 |
Buy |
0.79 |
30,000 |
23,667 |
376,250 |
| Silverman Joshua | CEO and President |
Jan 05 '26 |
Buy |
0.78 |
30,000 |
23,493 |
346,250 |
| SCHECHTER JONATHAN | Director |
Jan 07 '26 |
Buy |
0.84 |
20,000 |
16,872 |
192,500 |
| SCHECHTER JONATHAN | Director |
Jan 06 '26 |
Buy |
0.79 |
20,000 |
15,808 |
172,500 |
| SCHECHTER JONATHAN | Director |
Jan 05 '26 |
Buy |
0.78 |
20,000 |
15,552 |
152,500 |
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):